May 21, 2022

The Catholic Transcript

Complete News World

New SARS-CoV-2 strains of Govit-19 have been identified in the UK

New SARS-CoV-2 strains of Govit-19 have been identified in the UK

New SARS-CoV-2 strains of Govit-19 have been identified in the UK

A new analysis Health Care Agency Of United Kingdom Examined 3 types of restructuring of SARS – Cove-2It causes Govit-19, And also known as XF, XE and XD. Of these, XD and XF are readjustments of the delta and Ómicron BA.1 variants, while XE is a readjustment of the variants micron BA.1 and BA.2.

If a person is affected by 2 or more variants at the same time, a restorative variation occurs as a result of the combination of genetic material in the patient’s body. This is not an uncommon occurrence as several recombinant strains of SARS-CoV-2 have been identified during infections.

In the UK, 38 cases of XF restructuring variant have been identified, but no infection has been diagnosed since mid-February and there is no evidence of social transmission in the UK.

Reconstruction XD variant has been identified in 49 cases worldwide, most of which are in France.

In the case of the reconstruction XE variant of Ómicron BA.1 and BA.2, 637 cases have been confirmed so far in the UK. The first was dated January 19, 2022. The UK Health Care Agency notes that there is insufficient evidence to make conclusions about the developmental benefit or other characteristics of this variant.

Susan Hopkins, chief medical consultant at the UK Health Safety Agency, was quoted in a statement as saying, “Reconnected variants are not uncommon, especially when there are multiple variations in circulation and many infections are identified throughout. Like most other variants, most die relatively quickly.” “

Data from the UK Health Safety Agency estimate that the Ómicron BA.2 variant is currently the dominant variant in the UK, accounting for approximately 93.7% of cases in the UK.

See also  Britain prepares for the end of Elizabeth II's rule

This BA.2 variant continues to show significant growth over other Ómicron genera in circulation in the UK. A current review by the UK Health Safety Agency found no evidence that hospitalized risk was higher than micron BA.1 compared to Ómicron BA.1.